37866-45-8

Basic information

• Product Name: 2-AMINOOXYETHYLAMINE DIHYDROCHLORIDE
• Synonyms: 2-AMinoethoxyaMine Dihydrochloride;2-(AMinooxy)ethanaMine dihydrochloride;O-(2-AMinoethyl)hydroxylaMine Dihydrochloride;EthanaMine, 2-(aMinooxy)- (dihydrochloride);2-AMINOOXYETHYLAMINE DIHYDROCHLORIDE;2-(O-aminooxy)ethylamine dihydrochloride;O-(2-aminoethyl)hydroxylamine;2-(AMINOOXY)ETHYLAMINE 2HCL
• CAS NO: 37866-45-8
• Molecular Formula: C₂H₈N₂O*2ClH
• Molecular Weight: 149.0196
• EINECS: 412-310-7
• Product Categories: Aliphatics;Amines
• Mol File: 37866-45-8.mol
• Article Data: 7

Chemical Properties

• Melting Point: 205-207°
• Boiling Point: 257.4 °C at 760 mmHg
• Flash Point: 109.5 °C
• Appearance: /
• Vapor Pressure: 0.0115mmHg at 25°C
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• Solubility: DMSO (Slightly), Methanol (Slightly)
• Stability: Hygroscopic
• CAS DataBase Reference: 2-AMINOOXYETHYLAMINE DIHYDROCHLORIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-AMINOOXYETHYLAMINE DIHYDROCHLORIDE(37866-45-8)
• EPA Substance Registry System: 2-AMINOOXYETHYLAMINE DIHYDROCHLORIDE(37866-45-8)

Safety Data

• Hazard Codes: Xi
• Statements: 43-52/53
• Safety Statements: 24-37-61
• HazardClass: IRRITANT
• Hazardous Substances Data: 37866-45-8(Hazardous Substances Data)

Usage

Description

2-AMINOOXYETHYLAMINE DIHYDROCHLORIDE is a white solid chemical compound that is utilized in various applications across different industries due to its unique properties.

Uses

Used in Pharmaceutical Industry:
2-AMINOOXYETHYLAMINE DIHYDROCHLORIDE is used as a chemical intermediate for the preparation of istaroxime analogs, which are important in the development of pharmaceuticals that can potentially improve cardiovascular health and treat related conditions.
Used in Chemical Synthesis:
As a white solid, 2-AMINOOXYETHYLAMINE DIHYDROCHLORIDE is also used in chemical synthesis processes, where it serves as a key component in the production of various compounds and materials with specific applications in different fields.

InChI:InChI=1/C2H8N2O.2ClH/c3-1-2-5-4;;/h1-4H2;2*1H

Upstream product

• 222960-38-5 N-(2-aminoethoxy)benzamide 
• 1259519-97-5 C₁₈H₁₆N₂O₄ 

Downstream Products

• 66953-87-5 1-(4-Chloro-phenyl)-7-(1,1-dioxo-1λ⁶-thiomorpholin-4-yl)-heptan-1-one O-(2-amino-ethyl)-oxime 
• 76852-19-2 1-(4-Chloro-phenyl)-4-morpholin-4-yl-butan-1-one O-(2-amino-ethyl)-oxime 
• 66883-27-0 7-[(Z)-2-Amino-ethoxyimino]-7-(4-chloro-phenyl)-heptanoic acid dimethylamide 
• 129412-73-3 virginiamycin S aminoethyloxime 
• 76852-17-0 1-(4-Chloro-phenyl)-4-[4-(2-hydroxy-ethyl)-piperazin-1-yl]-butan-1-one O-(2-amino-ethyl)-oxime 
• 1046809-08-8 3-[O-(2-aminoethyl)oxime]-(5α)-androstene-3,6,17-trione 
• 203737-93-3 istaroxime 
• 372105-27-6 namitecan 
• 18807-67-5 1,2-Ethanediylbis(phenylmethyl carbamate) 
• 178378-10-4 (1S,3AS,5S,7AR)-1-[(E)-2-aminoethoxyimino]methyl-5-phenyl-7a-methylperhydroinden-3a-ol 
• 61493-11-6 5-Methoxy-4'-nitrovalerophenone O-(2-aminoethyl)oxime hydrochloride 
• 1164483-81-1 fluvoxamine maleate 

Relevant articles and documents

Novel approach to the synthesis of istaroxime

Istaroxime 1, a novel cardiotonic agent with high efficiency and low toxicity was synthesized from dehydroepiandrosterone 2 using a novel approach that included epoxidation, ring-opening, substitution, and oximation. The new protocol without gas protection was milder than the reported approaches. The overall yield of the method was 24.1%.

MACROCYCLIC LACTONE DERIVATIVES AND USES THEREOF

The present invention provides compounds represented by Formula 1: wherein, R' is as defined in the specification, in all their stereoisomeric and tautomeric forms and mixtures thereof in all ratios, and their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, pharmaceutically acceptable polymorphs and prodrugs. The invention also relates to processes for the preparation of the compounds of Formula and pharmaceutical compositions containing them. The compounds and the pharmaceutical compositions of the present invention are useful for the treatment of inflammatory disorders and/or viral infections. The compounds and the pharmaceutical compositions of the present invention are also useful for the treatment of cancer.

17β-O-aminoalkyloximes of 5β-androstane-3β, 14β-diol with digitalis- like activity: Synthesis, cardiotonic activity, structure-activity relationships, and molecular modeling of the Na+,K+-ATPase receptor

A series of digitalis-like compounds with a 17-aminoalkoxyiminoalkyl or -alkenyl substituent was synthesized and evaluated for inhibition of Na+,K+-ATPase and for inotropic activity. The highest inhibition was found with compounds having the substituent in configuration 17β and the amino group at a distance of 6 or 7 bonds from C(17) of the digitoxigenin skeleton. The presence of the oxime function strengthens the interaction with the receptor, more if α,β-unsaturated, thus mimicking the electronic situation of the unsaturated lactone in natural digitalis compounds. The most active compounds showed Na+,K+-ATPase inhibitory potencies (IC50) 17-25 times higher than the standards digitoxigenin and digoxin and 3-11 times higher inotropic potencies (EC50) in isolated guinea pig left atria. These features are supported by a molecular model suggesting the possible interactions of the groups described above with particular amino acid residues in the H1-H2 domains of Na+,K+-ATPase. Some interactions are the classical ones already described in the literature; a new, very strong interaction of the basic group with the Cys138 was found and adds new possibilities to design compounds interacting with this region of the receptor. The most interesting compounds were also studied in vivo in the anesthetized guinea pig for evaluating their inotropic effect versus the lethal dose. Compounds 9 and 12 showed a slightly higher safety ratio than digoxin and deserve further evaluation.